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Similar to many hospitals worldwide, Aberdeen Royal
Infirmary has had an outbreak of methicillin-resistant
Staphylococcus aureus (MRSA). In this setting, the out-
break is attributable to two major clones. The relationships
between antimicrobial use and MRSA prevalence were
analyzed by time-series analysis. From June 1997 to
December 2000, dynamic, temporal relationships were
found between monthly %MRSA and previous %MRSA,
macrolide use, third-generation cephalosporin use, and flu-
oroquinolone use. This study suggests that use of antimi-
crobial drugs to which the MRSA outbreak strains are
resistant may be an important factor in perpetuating the
outbreak. Moreover, this study confirmed the ecologic
effect of antimicrobial drug use (i.e., current antimicrobial
use) may have an effect on resistance in future patients.
Although these results may not be generalized to other
hospitals, they suggest new directions for control of MRSA,
which has thus far proved difficult and expensive.
A
ntimicrobial drug resistance occurs in hospitals
worldwide. One of the most globally important
microorganisms is methicillin-resistant Staphylococcus
aureus (MRSA), which now causes more than 40% of all
S. aureus bacteremias in the United Kingdom (1).
Measures to control MRSA outbreaks have concentrated
on transmission of the organism and prospective screening
for carriage, in combination with general infection control
measures such as patient isolation, use of barrier precau-
tions, and environmental decontamination (2). Eradicating
MRSA colonization has also been used to curb the spread
of MRSA. Despite these measures, incidences of MRSA
continue to rise (2,3). Guidelines for controlling MRSA in
hospitals rarely include information on controlling antimi-
crobial use, possibly because relatively little data quantify
the relationships between antimicrobial use and MRSA
rates, especially in outbreak situations (4–8). To date,
mathematical modeling has predicted that the effect of
antimicrobial prescribing patterns in an outbreak situation
is likely to be slight (9). 
Epidemic MRSA type 15 (EMRSA-15) is presently the
most common clone in the United Kingdom, followed by
EMRSA-16, both of which are termed “super-clones”
because of  their potential for spreading nationally and
internationally (10). Compared to other MRSA in the
United Kingdom, EMRSA-15 and EMRSA-16 are more
successful at surviving, colonizing, and spreading in the
hospital environment (11). Both clones are typically resist-
ant to all β-lactams, macrolides, and fluoroquinolones
(10). The northeast of Scotland has seen a rapid spread of
EMRSA-16 and, to a lesser extent, of EMRSA-15 during
the last 7 years after they first emerged in the area’s main
teaching hospital, Aberdeen Royal Infirmary. 
We investigate the dynamics of the MRSA outbreak at
Aberdeen Royal Infirmary and possible relationships
between MRSA prevalence and antimicrobial drug use, by
time-series analysis. Time-series analysis creates a mathe-
matical model to fit a series of dynamic observations to
forecast future behavior on the basis of retrospective behav-
ior. Unlike other statistical methods that assume observed
data to be independent, time-series analysis takes into
account the stochastic dependence of consecutive observa-
tions or autocorrelation (12,13). This method is appropriate
when data are measured repeatedly at equal intervals for
long periods and when these intervals are much shorter than
the study period. Time-series analysis has been applied in
medical specialties such as endocrinology, cardiology,
environmental medicine, and the study of chronic diseases
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analysis is considered the strongest quasi-experimental
method to ascertain the longitudinal effect of healthcare
interventions (13–15). Additionally, extensions of this
method, e.g., transfer function modeling and econometric
dynamic modeling, can take into account external factors
that may influence the target series over time and can
demonstrate a temporal relationship between these external
factors and the target series (13–15). Because series of
antimicrobial drug use data and resistance data always
show an autocorrelation, this method has been proposed by
López-Lozano et al. to study the relationship between
antimicrobial drug use and resistance (16). 
Materials and Methods
Aberdeen Royal Infirmary is a 1,200-bed tertiary refer-
ral hospital covering a population of approximately
500,000. It comprises various medical and surgical spe-
cialties and is close to other specialized hospitals. For each
month of the study period, January 1, 1996, to December
31, 2000, numbers of inpatient-days per ward were
obtained from the hospital’s admission department. During
the study period, all S. aureus isolated were screened for
susceptibility to methicillin by the comparative disc sus-
ceptibility test method on nutrient agar at 30°C with 48 h
incubation (17). Methicillin resistance was confirmed by
carrying out an Etest MIC. Susceptibility of the S. aureus
isolates to a range of additional antimicrobial drugs was
established by the comparative disc test method (17).
Additionally, the Aberdeen MRSA outbreak was investi-
gated by the Scottish MRSA Reference Laboratory, which
conducted independent confirmation and genotyping. The
Reference Laboratory carried out multiplex polymerase
chain reaction (PCR) with primers to mecA, nuc, rRNA,
16S rRNA, (18–20) and pulsed-field gel electrophoresis
(PFGE) typing of SmaI digested DNA (21). 
Monthly data for all S. aureus on which antimicrobial
drug susceptibility tests were carried out were exported
from the clinical microbiology information system into a
database. Information stored included patient identifier,
hospital, ward, specimen type, and antimicrobial drug–sus-
ceptibility pattern. Because we did not systematically and
uniformly search for MRSA carriers, isolates obtained
from surveillance screening were excluded. Only the first
S. aureus isolate from each patient within 7 days was
exported from the clinical microbiology laboratory infor-
mation system into an Access (Microsoft, Redmond, WA)
database. Variations in the antimicrobial susceptibility pat-
tern of S. aureus isolates from the same patient within the
7-day period were not considered. From these data, the
monthly prevalence of MRSA isolates was calculated as a
percentage, where the denominator was the total number
of S. aureus tested for methicillin resistance. 
Monthly quantities of all antimicrobial drugs delivered
to each hospital ward during the study period were export-
ed from the pharmacy information system and stored both
at the individual antimicrobial drug and class level in an
Access (Microsoft) database. Antimicrobial drug use was
expressed as a number of defined daily doses (DDDs) per
1,000 patient days, where the DDD for each antimicrobial
drug was defined by the World Health Organization
(WHO) (22). As in most hospitals, data on patient expo-
sure to antimicrobial drugs were not available at Aberdeen
Royal Infirmary. For a specific antimicrobial drug class,
however, the number of DDDs approximates the average
number of patients exposed to an antimicrobial drug from
this class each day. This measurement is the unit WHO
recommends to express ecologic pressure attributable to
antimicrobial drugs (23). 
Time-series analysis was carried out to explore the rela-
tionships between each antimicrobial drug use series and
the %MRSA series. For this purpose, linear transfer func-
tion models were built according to the identification
method proposed by Pankratz (15). This analysis was com-
pleted by a graphic exploration of the series. Line plots at
monthly time intervals were produced for the %MRSAand
for use of each antimicrobial drug class to visualize their
evolution over time and to confirm the relationships
between %MRSA and antimicrobial drug use. 
Once the basic characteristics (i.e., autocorrelation, sea-
sonality, and general trend) of each of the %MRSA and
antimicrobial drug use series were established, a multivari-
ate analysis was performed to quantify the relationships
between use of several antimicrobial classes and %MRSA
through the use of econometric dynamic time-series mod-
eling techniques (14,24,25). Specifically, polynomial dis-
tributed lag (PDL) modeling was used to detect and
quantify lagged effects of antimicrobial drug use on
%MRSA. The details of the modeling technique are pre-
sented in the Appendix. For the purposes of this study, data
were analyzed with Eviews 4.0 (Quantitative Micro
Software, Irvine, California, USA). 
Results
From January 1996 through December 2000, the clini-
cal microbiology laboratory isolated 9,441 nonduplicate,
nonsurveillance  S. aureus, including MRSA and methi-
cillin-susceptible S. aureus (MSSA), from 6,412 hospital-
ized patients. Numbers ranged from 97 to 241 S. aureus
isolates per month and demonstrated no seasonal patterns
(Figure 1). The annual %MRSA from 1996 to 2000 were
0.6, 5.0, 14.9, 24.1, and 31.9, respectively. MRSA were
rarely isolated before December 1996; after that date, a
sustained increase was observed, with marked peaks of
%MRSA observed in April 1998 (22%), April 1999
(30.5%), and February 2000 (38.2%) (Figure 1). Basic
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showed a spring seasonal variation of MRSA but no such
seasonal variation for MSSA (Figure 1). From 1997 to
2000, the epidemic clones, EMRSA-16 and EMRSA-15,
represented 80.0% and 15.4%, respectively, of 584 MRSA
strains submitted for genotyping to the Scottish MRSA
Reference Laboratory. Both clones were typically resistant
to all β-lactams, macrolides, and fluoroquinolones but oth-
erwise susceptible to other agents tested. The percentage
of co-resistance to other antimicrobial drugs in all nondu-
plicate, nonsurveillance MRSAs (EMRSA-16, EMRSA-
15, and other MRSA) isolated at Aberdeen Royal
Infirmary during the outbreak is presented in Table 1.
From 1996 to 2000, the annual use of systemic antibacter-
ial agents showed little variation: 837, 953, 919, 963, and
938 DDD/1,000 patient-days, respectively. However,
major variations occurred in the monthly use and season-
ality of individual classes of antimicrobial drugs (Table 2). 
Time-series analysis showed that %MRSA had a rela-
tionship with the use of many antimicrobial drug classes.
The relationship was strongest for macrolides, fluoro-
quinolones, and penicillins with β-lactamase inhibitors,
whereas other classes showed a significant but weaker
relationship (Table 3). Graphic exploration confirmed
these findings and pointed at third-generation
cephalosporin use as another series to be introduced in the
initial multivariate model (Figure 2). We also examined
scatter plots and correlations of %MRSA with use of indi-
vidual classes of antimicrobial drugs with up to 8-month
delays (online Appendix Figure, available at http://www.
cdc.gov/ncidod/eid/vol10no8/02-0694_app.htm). How-
ever, this last approach proved less useful than time-series
analysis, and graphic exploration of the time series in iden-
tifying relationships and optimal delays between antimi-
crobial drug use and %MRSA and could be misleading.
For example, scatter-plots and correlations showed an
inverse correlation between MRSA and tetracycline use.
However, graphic exploration showed that this correlation
reflected opposite general trends rather than monthly par-
allel variations between these two variables (Figure 2).
A multivariate PDL model was built to relate %MRSA
with use of these classes of antimicrobial drugs. The final
model included previous monthly %MRSA as well as use
of macrolides, third-generation cephalosporins, and fluo-
roquinolones as independent variables responsible for
variations in %MRSA(Table 4). The greatest total effect of
antimicrobial drug use on the %MRSA was found within
the first two or three significant lag periods, after which
the effect progressively decreased to reach nonsignificant
values a few months after the end of the direct effect. 
The sum of the direct and indirect effects of 10
DDD/1,000 patient-days or 30 more patients treated with a
macrolide (Table 4) was an increase in %MRSA by the
value 2.84 after 8 months. This change in antimicrobial
drug use had more effect on the %MRSA in 1997 than in
2000. For example, in June 1997 the %MRSA was 3.6%.
According to our model, an increase in macrolide use of 10
DDD/1,000 patient-days, or 30 more treated patients,
made the %MRSArise to 3.6 + 2.84 = 6.4% after 8 months
or an 81% increase over June 1997. In June 2000, the
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Figure 1. Evolution of the monthly number of clinical nonduplicate
Staphylococcus aureus and methicillin-resistant S. aureus (MRSA)
isolates and monthly %MRSA, Aberdeen Royal Infirmary, January
1996–December 2000.
Table 1. Antimicrobial drug coresistance in methicillin-resistant Staphylococcus aureus  (MRSA) isolates and in methicillin-susceptible 
S. aureus (MSSA), Aberdeen Royal Infirmary, 1997–2000 
MRSA isolates  MSSA isolates  
Antimicrobial drug  
No. tested for 
coresistance  No. resistant (%)  
No. tested for 
coresistance  No. resistant (%)   Risk ratio  p value 
Ciprofloxacin  1,218  1,195 (98.1)  515  183 (35.5)  13.4  < 0.0001 
Clindamycin  2,722  2,666 (97.9)  7,715  956 (12.4)  89.6  < 0.0001 
Erythromycin  2,721  2,669 (98.1)  7,701  1,115 (14.5)  90.0  < 0.0001 
Fusidic acid  2,736  36 (1.3)  7,798  636 (8.2)  0.20  < 0.0001 
Gentamicin  1,350  11 (0.8)  3,276  44 (1.3)  0.68  NS
a 
Mupirocin  2,514  154 (6.1)  5,180  99 (1.9)  1.92  < 0.0001 
Rifampin  1,005  62 (6.2)  72  8 (11.1)  0.95  NS 
Tetracycline  997  109 (10.9)  468  94 (20.1)  0.76  < 0.0001 
Trimethoprim  1,060  18 (1.7)  0  –  –  – 
aNS, nonsignificant.  %MRSAhad reached 32.1%. An increase in macrolide use
of 10 DDD/1,000 patient-days, or 30 more treated patients,
made the %MRSA rise to 32.1 + 2.84 = 34.9% after 8
months or a 9% increase over June 2000. This observation
suggests that antimicrobial drug use was a more important
ecologic risk factor at the start of the outbreak than once
MRSA had become endemic in the hospital. However,
macrolide use kept increasing during the study period
(Figure 2), which compensated for the decrease in the size
of the effect of antimicrobial drug use on %MRSA. Similar
effects were observed for third-generation cephalosporin
and fluoroquinolone use, i.e., an increase of 10 DDD per
1,000 patient-days on a certain month or 30 more treated
patients, resulted in an increase in %MRSA by 4.99 after
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Table 2. Characteristics of the monthly antimicrobial use time series, January 1996–December 2000.  
Antimicrobial drug class  
Average monthly use
a  
(minimum–maximum)  Trend
b  Seasonality
c 
Combinations of penicillins with β-lactamase inhibitors   228.6 (119.9–334.9)  Upward  Yes (0.294) 
β -lactamase resistant penicillins   116.1 (49.1–202.1)  No  No 
Macrolides  90.2 (32.7–177.9)  Upward  Yes (0.371) 
Penicillins with extended spectrum   90.1 (43.9–177.4)  No  No 
Third-generation cephalosporins   62.5 (43.8–103.1)  Upward  Yes (0.226) 
β -lactamase-sensitive penicillins    54.6 (0–110.5)  No  No 
Combinations of sulfonamides and trimethoprim, 
including derivatives  
52.9 (0–86.8)  No  No 
Fluoroquinolones   51.9 (19.4–87.5)  Upward  No 
Second-generation cephalosporins   32.9 (5.3–87.1)  Downward  No 
Other antibacterial drugs
d   32.7 (16.3–45.9)  Upward  No 
Tetracyclines  30.9 (0–63.4)  Downward  No 
Aminoglycosides   24.8 (11.8–44.1)  Upward  Yes (0.236) 
Glycopeptides  13.5 (4.6–25.5)  Upward  No 
Lincosamides  6.1 (0–15.7)  Upward  Yes (0.208) 
First-generation cephalosporins   5.2 (0.7–14.5)  No  No 
Carbapenems  4.0 (0–8.5)  No  No 
aDefined daily doses (DDD) per 1,000 mean patient-days.
 
bBased on regression of the series on time (according to the results of Dickey-Fuller unit root  tests, none of the series needed to be differenced).   
cAutocorrelation of order 12, based on the correlogram and the partial correlogram. When seasonality was present, the figure in parenthesis indicates the 
estimated autocorrelation of order 12, i.e., the correlation between antimicrobial use on a given month and use on the same month 1 year before.
  
dAmphenicols, monobactams, other quinolones, imidazoles, fusidic acid, and nitrofurantoin derivatives.  
Table 3. Summary of transfer function models explaining the monthly %MRSA by use of each antimicrobial drug class
a  
Antimicrobial class
b  Average delay (months)   Direction of effect
c  p value  R
2 d 
Combinations of penicillins with β-lactamase 
inhibitors 
2 
4 
Positive 
Positive 
0.04 
0.01 
0.92 
β  −lactamase-resistant penicillins   0 
6 
Negative 
Positive 
0.02 
0.002 
0.90 
Macrolides  1  Positive  0.0001  0.93 
Penicillins with extended spectrum   1  Positive  0.03  0.91 
Third-generation cephalosporins   1  Positive  0.04  0.90 
β −lactamase sensitive penicillins    6  Positive  0.04  0.89 
Combinations of sulfonamides and trimethoprim, 
including derivatives  
4  Positive  0.02  0.90 
Fluoroquinolones   4  Positive  0.0004  0.92 
Second-generation cephalosporins         No relationship  
Other antibacterials
e  0  Positive  0.002  0.91 
Tetracyclines  4 
7 
Positive 
Negative 
0.03 
0.0007 
0.91 
Aminoglycosides         No relationship  
Lincosamides  7  Positive  0.02  0.89 
First-generation cephalosporins         No relationship  
Carbapenems  3  Positive  0.03  0.90 
aMRSA, methicillin-resistant Staphylococcus aureus .
 
bGlycopeptide use is not presented in this table because it showed an inverse relationship with %MRSA. In other words, %MRSA explained the monthly 
variations of glycopeptide use and not the reverse (Discussion).  
cPositive direction of effect: increase in antimicrobial use results in increase in %MRSA and inversely. Negative direction of effect: increase in 
antimicrobial use results in decrease in %MRSA and inversely.  
dAll models include the variable %MRSA with a 1 -month delay and a p value < 0.0001.   
eAmphenicols, monobactams, other quinolones, imidazoles, fusidic acid, and nitrofurantoin derivatives.  12 months for third-generation cephalosporins and by 4.40
after 11 months for fluoroquinolones. 
The determination coefficient (R2) of the final model
was 0.902, i.e., 90.2% of the variations of the monthly
%MRSA from June 1997 to December 2000 were
explained by the model. The model that did not take
antimicrobial drug use into account (i.e., considered previ-
ous monthly %MRSA) had a lower determination coeffi-
cient (0.811) and over- or underestimated the monthly
%MRSAby 7.93%. The model that took into account both
previous monthly %MRSA and previous use of the three
key classes of antimicrobial drugs, with a determination
coefficient of 0.902, produced an average discrepancy of
2.84 percentage points with the observed %MRSA.
Therefore, taking antimicrobial drug use into account
helped to improve the precision in forecasting the monthly
%MRSA by 64%, which is a clear indication that antimi-
crobial drug use has a substantial causal effect on the
%MRSA. 
We compared coresistance patterns of MRSA isolates
from the outbreak (i.e., 1997–2000) and of MSSAfrom the
same period (Table 1), which confirmed the consistency of
the antimicrobial drug use included in the model. MRSA
isolates from the outbreak period were almost always
resistant to erythromycin, clindamycin, and ciprofloxacin,
whereas MSSA isolates from the same period were resist-
ant in 14.5%, 12.4%, and 35.5% of cases, respectively.
Resistance of MRSA isolates to the other antimicrobial
drugs tested never exceeded 11% and was lower than in
MSSA isolates with the exception of mupirocin (6.1% in
MRSA isolates, 1.9% in MSSA isolates). 
Finally, a curve of the summed monthly use of
macrolides, third-generation cephalosporins, and fluoro-
quinolones, which took into account their respective lags
for direct effects, was constructed and plotted on the same
graph as monthly %MRSA (Figure 3). This figure shows
the striking parallel nature of the relationship between the
lagged use of these specific antimicrobial classes and the
%MRSAat Aberdeen Royal Infirmary, which confirms the
findings visually.
Discussion 
For the first time, a powerful statistical model provides
evidence of a strong temporal relationship between antimi-
crobial drug use and the varying prevalence of MRSAover
time during an outbreak in a single hospital. The fact that
only three classes of antimicrobial drugs, namely third-
generation cephalosporins, fluoroquinolones, and
macrolides, showed this relationship is not surprising. In
the past, exposures to cephalosporins (26,27), fluoro-
quinolones (27–32), and macrolides (30) have been report-
ed as patient risk factors for MRSA infection or
colonization. And cephalosporin (4,8,33,34), fluoro-
quinolone (5,8,33), and macrolide use (8) have been
reported  as ecologic risk factors for high, or parallel vari-
ations of, MRSA prevalence or incidence. At Aberdeen
Royal Infirmary, MRSAisolates were typically resistant to
macrolides and fluoroquinolones (Table 1). Additionally,
third-generation cephalosporins have poor activity against
MRSA. At the same time, macrolides (clarithromycin and
erythromycin), third-generation cephalosporins (mainly
cefotaxime), and fluoroquinolones (essentially
ciprofloxacin) were among the most used antimicrobial
drugs at Aberdeen Royal Infirmary (Table 2), thus provid-
ing MRSA isolates with an ecologic advantage over other
bacteria. Although the Aberdeen Royal Infirmary MRSA
isolates were almost always resistant to clindamycin, use
of lincosamides was among the lowest, which might
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Figure 2. Examples of graphic exploration of the relationship
between the monthly % methicillin-resistant Staphylococcus
aureus (%MRSA) and the monthly use of individual classes of
antimicrobials, Aberdeen Royal Infirmary, January 1996-
December 2000 (  , %MRSA;  –, Antimicrobial use, 5-month mov-
ing average, right Y-axis); A) penicillins with β-lactamase inhibitors,
B) macrolides, C) third-generation cephalosporins, D) fluoro-
quinolones, E) tetracyclines, and  F) aminoglycosides.explain why it did not appear as a risk factor in the multi-
variate model. 
In addition to antimicrobial drug use, the final model
also included the %MRSA observed 1 month before. As
mentioned, we did not uniformly look for MRSAcoloniza-
tion. The pressure attributable to MRSA-colonized
patients is a known risk factor for MRSA acquisition
(8,35), which in turn affects the number of MRSA infec-
tions and the %MRSA in S. aureus from clinical samples.
We therefore think that the %MRSA observed 1 month
before is a surrogate for the pressure attributable to
MRSA-positive patients during the past month.
The study was an ecologic and uncontrolled observa-
tional study in a single hospital. Selection bias was unlike-
ly because data represented all hospitalized patients.
Information bias was unlikely because data were not
specifically collected for our study but for other purposes,
i.e., routine clinical microbiologic diagnosis for S. aureus
data and pharmacy accounting for antimicrobial drug use
data. Confounding factors cannot be excluded but are
unlikely for two reasons. First, as a result of the applied
modeling strategy, the monthly variation in %MRSA not
explained by the model (9.8%) was random. Therefore, the
role of any possible unidentified confounding variable is
thought to be minimal. Second, infection control policies,
including measures such as barrier nursing, single room
isolation, and eradication of carriage have consistently
been applied to all MRSApatients during the study period,
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Table 4. Estimated multivariate  polynomial distributed lag (PDL) model for monthly %MRSA (R
2=0.902)
a 
Direct effect
b  Indirect effect
c  Sum of both effects
d 
Explaining variable   Lag (mo.)  Coeff  T-stat  p  Coeff  Coeff
e  T-stat  p 
%MRSA  1  0.420  3.96  0.0003         
Macrolide use                 
Each month  1  0.083        0.083  4.02  0.0003 
  2  0.055      0.035  0.090  5.34  <0.0001 
  3  0.027      0.038  0.065  6.02  <0.0001 
  4        0.027  0.027  3.16  0.003 
Overall  1–3  0.165  4.02  0.0003         
  2–4        0.100       
  1–4          0.265     
Third-generation 
cephalosporin use  
               
Each month  4  0.116        0.116  2.75  0.009 
  5  0.087      0.049  0.136  3.27  0.002 
  6  0.058      0.057  0.115  3.70  0.0007 
  7  0.029      0.048  0.077  3.91  0.0004 
  8        0.032  0.032  2.75  0.009 
Overall  4–7  0.290  2.75  0.009         
  5–8        0.186       
  4–8          0.476     
Fluoroquinolone use                  
Each month  4  0.170        0.170  3.43  0.002 
  5  0.085      0.071  0.156  3.37  0.002 
  6        0.066  0.066  2.31  0.03 
Overall  4–5  0.255  3.43  0.002         
  5–6        0.137       
  4–6          0.392     
Constant    –36.7  –4.42  0.0001         
aMRSA, methicillin-resistant Staphylococcus aureus.
 
bPast %MRSA as well as past use of these three antimicrobial drug classes had direct effects on %MRSA. These direct effects diminished the longer the lag time.  
cBecause every increase in %MRSA by the value 1 was followed the next month by a significant increase in %MRSA by the value 0.420, use of the three 
antimicrobial drug classes also had indirect effects on the %MRSA. As 0.420 is <1, these indirect effects necessarily vanished over time. As an example,  
decreasing indirect effects are only presented for a few months. There were substantial indirect effects of macrolide use up to month 8 (final coefficient for 
sum of both effects = 0.284), of third -generation cephalosporin use up to month 12 (final coefficient for sum of both effects = 0.499), and of 
fluoroquinolone use up to month 11 (final coefficient for sum of both effects = 0.440).  
dEach month, the total effect of each class of antimicrobial on the %MRSA resulted from the sum of the direct and indirect effects.  
eThe estimated coefficients indicate the values by which the %MRSA would increase in response to an increase in 1 DDD per 1,000 patient-days for each 
of the three significant antimicrobial classes, when all other variables remain constant. Since the average figure for monthly patient-days at Aberdeen 
Royal Infirmary is 22,800, 10 DDD per 1,000 patient-days correspond to approximately 230 DDD per month or thirty 7- to 8-day antimicrobial courses. For 
example, an increase in macrolide use by 10 DD D per 1,000 patient -days on a certain month, or 30 more patients treated with a macrolide as compared 
with the previous month, would lead to a direct increase in %MRSA by 0.83, 1 month later, by 0.55, 2 months later and by 0.27, 3 months later. The total 
direct effect would therefore be evident after 3 months, amounting to an increase in %MRSA by the value 1.65. Additionally, %MRSA indirectly 
attributable to macrolide use would increase by the value 0.35 (i.e., 0.83 x 0.42) after 2 months and by 0.38 (i.e.. [0.83 x 0.42] + [0.55 x 0.42]) after 3 
months. From the 4th month onwards, there would be no direct effect of macrolide use on the %MRSA, only ever-decreasing indirect effects that would 
practically disappear after 8 months (decreasing effects in months 5 to 8 not shown).  
 although a shortage of single rooms often necessitated sev-
eral MRSA-positive patients being assigned to a single
nurse. Staff MRSA carriers were not actively sought, but
use of gloves and hand washing, as appropriate, were con-
stantly emphasized. Active patient contact tracing was
applied, when possible, but environmental cleaning relied
on standard cleaning schedules rather than environmental
screening and targeted interventions. This policy was in
line with national guidelines (36). The relationships
between antimicrobial drug use and the %MRSA were
unlikely to be attributable to chance because p values in
the model were low. Additionally, the cause-effect rela-
tionships in the model were validated by their temporal
nature (i.e., use of macrolides, third-generation
cephalosporins, and fluoroquinolones always preceded
%MRSA). Additionally, for each of these antimicrobial
drug classes, the effect of antimicrobial drug use on the
%MRSA was directional (i.e., an increase in use resulted
in increased %MRSA and a decrease in use resulted in
decreased %MRSA). In contrast, variations in glycopep-
tide use followed variations in %MRSA with an average
delay of 1 month (coefficient = 0.45). 
The relative importance of antimicrobial drug use com-
pared to cross-transmission or changes in the patient case-
mix could not be assessed. In ecologic analyses with
aggregated data, additional data, such as volumes of med-
icated soaps or alcoholic solutions used for hand hygiene,
could be used as surrogates for infection control practices;
however, these data were not available. As in many hospi-
tals, patient-level data were not available, which is why we
modeled aggregated microbiology and pharmacy data.
Models that use patient-level data on both antimicrobial
drug exposure and MRSA may reach different conclu-
sions. For example, the risk period for a patient for acquir-
ing MRSA then developing an infection would be limited
to hospital stay, which is generally short and rarely longer
than 1 month. However, our model showed that a delay of
several months was sometimes necessary to observe an
ecologic effect of antimicrobial drug use on the %MRSA.
This result is difficult to interpret since it means that
antimicrobial drug exposure of some patients on a certain
month has an impact on MRSAinfections in other patients
several months later. Since antimicrobial drug use data are
based on dispensations to the wards, antimicrobial drugs
can be stocked in the wards and used over several months.
However, pharmacy data showed that antimicrobial agents
were dispensed several times per ward each month, mak-
ing this explanation unlikely. Another explanation could be
that the increase in antimicrobial drug use would con-
tribute to increasing the size of the reservoir of MRSAcar-
riers. First, MRSA clones would be selected in
antimicrobial drug-exposed patients. Then, the size of the
reservoir of MRSA carriers would gradually increase
through the spread of these MRSAclones to other patients,
hospital staff, and the environment. This increase would
become evident in clinical samples after several months
when the MRSAreservoir reached a certain size. For fluo-
roquinolones, this hypothesis is supported by the results of
Bisognano et al. (37) and Harbarth et al. (31). These
authors showed that sub-MIC levels of ciprofloxacin
increase adhesion of quinolone-resistant MRSA, which
could explain persistent MRSA carriage and failure of
mupirocin treatment in patients who received a fluoro-
quinolone. Antimicrobial drug use and cross-transmission
probably work together to influence the %MRSA, and if
all cross-transmission were to stop after implementing a
very successful control program, the relationship between
fluoroquinolone use and %MRSA would most probably
disappear. Further research is needed to confirm this
hypothesis and, more generally, to understand why long
delays are also observed for other antimicrobial drugs, e.g.,
third-generation cephalosporins.
At Aberdeen Royal Infirmary, antimicrobial drug pre-
scribing is overseen by an antibiotic committee, which
provides and regularly updates a joint hospital-community
antibiotic policy and stewardship program (38).
Antimicrobial prescribing audits are performed periodical-
ly, but changing prescribing practices to control MRSAhas
not been attempted. Third-generation cephalosporin pre-
scribing was addressed previously during an outbreak of
Klebsiella pneumoniae displaying extended-spectrum β-
lactamase activity (39). With the implementation of the
British Thoracic Society guidelines for treatment of com-
munity-acquired pneumonia (40), macrolide and third-
generation cephalosporin (mainly cefotaxime) prescribing
has increased, which has been paralleled by the increase in
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Figure 3. Evolution of the monthly % methicillin-resistant
Staphylococcus aureus (MRSA) and monthly sum of lagged
antimicrobial use as identified in polynomial distributed lag (PDL)
model: macrolides (lags of 1 to 3 months), third-generation
cephalosporins (lags of 4 to 7 months), and fluoroquinolones (lags
of 4 and 5 months), Aberdeen Royal Infirmary, January 1996-
December 2000.MRSA. As the Aberdeen MRSA clones are relatively sus-
ceptible, a policy of therapeutic substitution has been
implemented in MRSA problem areas, starting with the
replacement of cephalosporins by non–β-lactam antimi-
crobial drugs in surgical prophylaxis. The increase in  flu-
oroquinolone prescribing has not been explained, but
audits indicate that it is commonly used to treat serious
nosocomial gram-negative infection (38).
Our study showed a quantifiable, temporal relationship
between use of three classes of antimicrobial drugs
(macrolides, third-generation cephalosporins, and fluoro-
quinolones) and the %MRSA. Because the study was per-
formed in one hospital during an outbreak in which two
predominant strains were circulating, it might not apply to
other hospitals. Nevertheless, the use of antimicrobial
drugs other than anti-staphylococcal penicillins and to
which the MRSA outbreak strains are resistant might be a
factor that would promote the outbreak. Moreover, the
ecologic effect of antimicrobial drug use was confirmed
(i.e., current antimicrobial drug use might have an effect
on resistance in future patients). The effect of antimicro-
bial use on the %MRSA was greatest when the outbreak
started and decreased when the %MRSA increased. Large
decreases in antimicrobial drug use would have been need-
ed to affect MRSAonce it had become endemic. However,
programs to control prescriptions of selected antimicrobial
drug classes could represent an adjunct measure to active
surveillance cultures and barrier precautions for the con-
trol of clonal outbreaks of MRSA, which has proved diffi-
cult and expensive.
Dr. Monnet is a pharmacist and microbiologist working at
the National Center for Antimicrobials and Infection Control,
Statens Serum Institut, Copenhagen, Denmark, as part of the
Danish Integrated Antimicrobial Resistance Monitoring and
Research Programme. His research interests include surveillance
of antimicrobial resistance, surveillance of antimicrobial use, and
the relationship between antimicrobial use and resistance.
Appendix 
Polynomial Distributed Lag (PDL) model
A PDL model was built to detect and quantify the lagged
effects of antimicrobial use on the % methicillin-resistant
Staphylococcus aureus (MRSA). In a PDL model, the relation-
ship between the dependent variable (resistance) and the inde-
pendent variables (past resistance and antimicrobial use) should
evolve smoothly over time, through the use of “polynomial lags.”
The optimum PDL model was arrived at by the “general-to-spe-
cific” econometric methodologic characteristics. This meant that,
initially, many possible independent variables were included in
the model, some of which were ultimately found to be irrelevant.
Additionally, for all the independent variables, lags of up to 8
months were initially included to identify direct effects. The ini-
tial dynamic regression model with PDLs considering %MRSA
series as the dependent variable and several antimicrobial drug
use series as explanatory series was the following:
with PDL restrictions on the coefficients of antimicrobial use
and where MAC means macrolide use, 3GC third-generation
cephalosporin use, FQ fluoroquinolone use and PIB use of peni-
cillins with β-lactamase inhibitors. The model was initially esti-
mated on the full study period, i.e., January 1996–December
2000, using a degree qj of the polynomial equal to 3. The estimat-
ed model was compatible with normal white noise errors
(absence of autocorrelation and absence of heteroskedasticity),
and no signs of nonmodeled nonlinearities were seen. 
This initial model was then simplified to eliminate irrelevant
antimicrobial drug uses and unnecessary lags. In the first steps of
the simplification, all antimicrobial drugs were kept in the model,
and the simplification took the form of reducing the order of the
polynomial and eliminating unnecessary lags. Along this process,
use of penicillins with β-lactamase inhibitors did not appear to
play a significant role and was eliminated from the model. We
also tried to introduce use of each of the other antimicrobial drug
classes that showed a relationship in Table 3; however, none
appeared to play an important role, and they were not included in
the model. Further simplification of the distributed lags of
macrolide use, third-generation cephalosporin use, and fluoro-
quinolone use of the %MRSA itself led to a model in which,
through CUSUM and CUSUMSQ statistics, a structural change
was detected around the middle of 1997. Application of the Chow
test located the change in June 1997. The %MRSA was virtually
zero in 1996 and started to increase at the beginning of 1997,
which was consistent with the fact that the MRSA epidemic
strain, resistant to macrolides and fluoroquinolones, only became
predominant in 1997. In 1996, 56% and 50% of MRSA isolates
were resistant to erythromycin and ciprofloxacin, respectively,
whereas these percentages suddenly rose to 92% and 89%,
respectively, in 1997. Data before June 1997 were considered as
not being part of the outbreak and were therefore not included in
the final model. The validity of the simplified, final model from
June 1997 onwards was checked by a battery of specification and
diagnostic tests to verify the absence of autocorrelation of resid-
uals, absence of heteroskedasticity, normality of residuals,
absence of nonmodeled nonlinearities and absence of structural
change.
The basic measure of forecasting quality, Root Mean Squared
Error of Forecast (RMSEF) was also computed, which provided
an average measurement of the amount by which the model over-
or underestimated the %MRSA. RMSEF was calculated for a
model without antimicrobial drug use (based on past %MRSA
only) and compared with that of the final model, which included
antimicrobial drug use.
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